Literature DB >> 29389775

Apolipoprotein L1 nephropathies: 2017 in review.

Jeffrey B Kopp1, Hila Roshanravan, Koji Okamoto.   

Abstract

PURPOSE OF REVIEW: To review publications relating to apolipoprotein L1 (APOL1) renal risk variants published 2017. RECENT
FINDINGS: The study of APOL1 variants continues to be highly active; 24 articles published in 2017 were selected to highlight. These include clinical studies of kidney disease, kidney transplantation, hypertension, cardiovascular disease, and genetic diversity. Laboratory studies included APOL1 association with vesicle-associated membrane soluble N-ethylmaleimide-sensitive factor activating protein receptor protein and with soluble urokinase-type plasminogen activator receptor, mitochondrial dysfunction, endolysosomal dysfunction, and inflammasome activation.
SUMMARY: Our understanding of the role of APOL1 genetic variants and the mechanisms for renal toxicity continues to deepen. It is not yet clear which pathways are most relevant to human disease, and so, the most relevant drug targets remain to be defined.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29389775      PMCID: PMC7327739          DOI: 10.1097/MNH.0000000000000399

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  34 in total

1.  Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice.

Authors:  Pazit Beckerman; Jing Bi-Karchin; Ae Seo Deok Park; Chengxiang Qiu; Patrick D Dummer; Irfana Soomro; Carine M Boustany-Kari; Steven S Pullen; Jeffrey H Miner; Chien-An A Hu; Tibor Rohacs; Kazunori Inoue; Shuta Ishibe; Moin A Saleem; Matthew B Palmer; Ana Maria Cuervo; Jeffrey B Kopp; Katalin Susztak
Journal:  Nat Med       Date:  2017-02-20       Impact factor: 53.440

Review 2.  Therapeutics for APOL1 nephropathies: putting out the fire in the podocyte.

Authors:  Jurgen Heymann; Cheryl A Winkler; Maarten Hoek; Katalin Susztak; Jeffrey B Kopp
Journal:  Nephrol Dial Transplant       Date:  2017-01-01       Impact factor: 5.992

Review 3.  Podocyte energy metabolism and glomerular diseases.

Authors:  Toshiyuki Imasawa; Rodrigue Rossignol
Journal:  Int J Biochem Cell Biol       Date:  2013-06-24       Impact factor: 5.085

4.  Apolipoprotein L1 Variants and Blood Pressure Traits in African Americans.

Authors:  Girish N Nadkarni; Geneviève Galarneau; Stephen B Ellis; Rajiv Nadukuru; Jinglan Zhang; Stuart A Scott; Claudia Schurmann; Rongling Li; Laura J Rasmussen-Torvik; Abel N Kho; M Geoffrey Hayes; Jennifer A Pacheco; Teri A Manolio; Rex L Chisholm; Dan M Roden; Joshua C Denny; Eimear E Kenny; Erwin P Bottinger
Journal:  J Am Coll Cardiol       Date:  2017-03-28       Impact factor: 24.094

5.  APOL1 variants change C-terminal conformational dynamics and binding to SNARE protein VAMP8.

Authors:  Sethu M Madhavan; John F O'Toole; Martha Konieczkowski; Laura Barisoni; David B Thomas; Santhi Ganesan; Leslie A Bruggeman; Matthias Buck; John R Sedor
Journal:  JCI Insight       Date:  2017-07-20

6.  APOL1 genetic variants are not associated with longitudinal blood pressure in young black adults.

Authors:  Teresa K Chen; Michelle M Estrella; Eric Vittinghoff; Feng Lin; Orlando M Gutierrez; Holly Kramer; Cora E Lewis; Jeffrey B Kopp; Norrina B Allen; Cheryl A Winkler; Kirsten B Bibbins-Domingo; Carmen A Peralta
Journal:  Kidney Int       Date:  2017-05-23       Impact factor: 18.998

Review 7.  APOL1 Gene Kidney Risk Variants and Cardiovascular Disease: Getting to the Heart of the Matter.

Authors:  Nicholas O McLean; Todd W Robinson; Barry I Freedman
Journal:  Am J Kidney Dis       Date:  2017-01-28       Impact factor: 11.072

8.  APOL1 risk alleles among individuals with CKD in Northern Tanzania: A pilot study.

Authors:  John W Stanifer; Francis Karia; Venance Maro; Kajiru Kilonzo; Xuejun Qin; Uptal D Patel; Elizabeth R Hauser
Journal:  PLoS One       Date:  2017-07-21       Impact factor: 3.240

9.  APOL1-associated glomerular disease among African-American children: a collaboration of the Chronic Kidney Disease in Children (CKiD) and Nephrotic Syndrome Study Network (NEPTUNE) cohorts.

Authors:  Derek K Ng; Catherine C Robertson; Robert P Woroniecki; Sophie Limou; Christopher E Gillies; Kimberly J Reidy; Cheryl A Winkler; Sangeeta Hingorani; Keisha L Gibson; Rebecca Hjorten; Christine B Sethna; Jeffrey B Kopp; Marva Moxey-Mims; Susan L Furth; Bradley A Warady; Matthias Kretzler; John R Sedor; Frederick J Kaskel; Matthew G Sampson
Journal:  Nephrol Dial Transplant       Date:  2017-06-01       Impact factor: 5.992

10.  Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans.

Authors:  Michael S Lipkowitz; Barry I Freedman; Carl D Langefeld; Mary E Comeau; Donald W Bowden; W H Linda Kao; Brad C Astor; Erwin P Bottinger; Sudha K Iyengar; Paul E Klotman; Richard G Freedman; Weijia Zhang; Rulan S Parekh; Michael J Choi; George W Nelson; Cheryl A Winkler; Jeffrey B Kopp
Journal:  Kidney Int       Date:  2012-07-25       Impact factor: 10.612

View more
  4 in total

Review 1.  Macrophage polarization in innate immune responses contributing to pathogenesis of chronic kidney disease.

Authors:  Hewang Lee; Michael B Fessler; Peng Qu; Jurgen Heymann; Jeffrey B Kopp
Journal:  BMC Nephrol       Date:  2020-07-13       Impact factor: 2.388

2.  Prevalence of APOL1 Risk Variants in Afro-Descendant Patients with Chronic Kidney Disease in a Latin American Country.

Authors:  Carlos E Duran; Alejandro Ramírez; Juan G Posada; Johanna Schweineberg; Liliana Mesa; Harry Pachajoa; Mayra Estacio; Eliana Manzi; Vanessa Aros; Lorena Díaz; Victor H Garcia
Journal:  Int J Nephrol       Date:  2019-12-18

3.  Kidney-disease-associated variants of Apolipoprotein L1 show gain of function in cation channel activity.

Authors:  Jonathan Bruno; John C Edwards
Journal:  J Biol Chem       Date:  2021-01-09       Impact factor: 5.157

Review 4.  At the Research-Clinical Interface: Returning Individual Genetic Results to Research Participants.

Authors:  Kathleen M West; Erika Blacksher; Kerri L Cavanaugh; Stephanie M Fullerton; Ebele M Umeukeje; Bessie A Young; Wylie Burke
Journal:  Clin J Am Soc Nephrol       Date:  2020-02-10       Impact factor: 8.237

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.